Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
Not Applicable
Recruiting
- Conditions
- Lung Cancer
- Interventions
- Diagnostic Test: Ability to order FirstLookâ„¢Other: Continuing Medical Education for Lung Cancer
- First Posted Date
- 2023-11-24
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Delfi Diagnostics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06145750
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung
Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- Other: Blood Sample Collection
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Delfi Diagnostics Inc.
- Target Recruit Count
- 15000
- Registration Number
- NCT05306288
- Locations
- 🇺🇸
Hoag Hospital, Newport Beach, California, United States
🇺🇸Pittsburgh VA Healthcare System, Pittsburgh, Pennsylvania, United States
🇺🇸Allegheny Health Network, Pittsburgh, Pennsylvania, United States
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
Recruiting
- Conditions
- Lung CancerBladder CancerKidney CancerColorectal CancerLiver CancerHead and Neck CancerEsophageal CancerPancreas CancerSkin CancerStomach Cancer
- Interventions
- Other: Blood Sample Collection
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Delfi Diagnostics Inc.
- Target Recruit Count
- 2660
- Registration Number
- NCT04825834
- Locations
- 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath